Please login to the form below
buprenorphine
This page shows the latest buprenorphine news and features for those working in and with pharma, biotech and healthcare.
Troubled Alkermes eyes November OK for new antipsychotic
and buprenorphine – saying that there wasn’t enough evidence to show it was clinically effective.
Latest news
-
Insys gets bankruptcy court okay for Subsys sale
a naloxone nasal spray formulation and a sublingual spray formulation of buprenorphine in development. ... The buprenorphine spray product was however rejected by the FDA last year.
-
Reckitt hammered by $1.4bn opioid settlement bill
Suboxone, which is based on the powerful opioid drug buprenorphine, is approved for use by recovering opioid addicts to avoid or reduce withdrawal symptoms while they undergo treatment.
-
UK to add addiction warnings to opioids as use soars
Camurus gained EU approval for its weekly and monthly Buvidal (prolonged release buprenorphine) for the treatment of opioid dependence in November, the first approval of a long-acting treatment for opioid
-
CHMP nod for Alexion, GSK drugs, revocation for Lartruvo
Other drugs gaining recommendation included:. Molteni Farmaceutici’s Sixmo (buprenorphine) an opioid dependence implant treatment that releases low levels of buprenorphine into the patient’s body for six months.
-
Brexit contributes to surge in generic drug prices
He says some medicines would be “particularly vulnerable" - highlighting a current shortage of pain and opioid addiction treatment Buprenorphine and antipsychotic Risperidone, arising in particular because there are no simple alternatives
More from news
Approximately 1 fully matching, plus 22 partially matching documents found.
Latest Intelligence
-
As the opioid crisis grabs the headlines, the search for safe treatments continues
Indivior discovered buprenorphine, sold it under the brand name Subutex to treat opioid addiction in 1996 and has since expanded its portfolio with Suboxone tablets, Suboxone Film, the monthly injectable Sublocade ... of buprenorphine that addresses the
-
Drug launches to watch in 2019
CAM2038 is an injectable solution that slowly releases buprenorphine – the most common drug used to treat opioid addiction – into the body, eliminating the need for daily dosages as well as the
-
Pharma deals during December 2012
deal? Coincidentally, the third late stage deal this month is also an analgesic, a buprenorphine implant lasting for six months for maintenance treatment of opioid dependence; the NDA was submitted in ... 335. Titan / Braeburn. Commercialisation and
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- My journey advancing the science in pulmonary hypertension
- Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine
- A new era for UK-Japanese scientific research relations
- Dermavant publishes positive phase 3 data for treatment of plaque psoriasis
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia
- Alzheimer's Research UK supports government plans for clinical research
- GSK announces The HealthTree Foundation’s multiple myeloma programme as first ‘Think Tank’ challenge winner
- NRG Therapeutics partners with Domainex to develop neurodegenerative disease treatment
- Innovative Trials opens first US office
- Scanning for Health Indicators and Risks Through Your Smartphone
- A creative awakening – how pharma is bringing innovation to the patient journey
- Behaviour change – a maze of decisions influenced by personal habits, experiences and intentions
- My journey advancing the science in pulmonary hypertension
- Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine
- Novartis publishes final positive phase 3 results of Zolgensma in Nature Medicine
- Delivering content to fuel omnichannel engagement
PMHub
Syneos Health®
Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and...
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
